Europe Cervical Cancer Screening, Diagnostics, And Pre-Cancerous Dysplasia Lesion Treatment Market Size & Outlook
The cervical cancer screening, diagnostics, and pre-cancerous dysplasia lesion treatment market in Europe is expected to reach a projected revenue of US$ 4,252.7 million by 2035. A compound annual growth rate of 5.6% is expected of Europe cervical cancer screening, diagnostics, and pre-cancerous dysplasia lesion treatment market from 2025 to 2035.
Clinical Diagnostics
Cancer Diagnostics
Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment Market Outlook
Europe cervical cancer screening, diagnostics, and pre-cancerous dysplasia lesion treatment market highlights
The Europe cervical cancer screening, diagnostics, and pre-cancerous dysplasia lesion treatment market generated a revenue of USD 2,370.5 million in 2024.
The market is expected to grow at a CAGR of 5.6% from 2025 to 2035.
In terms of segment, cervical cancer screening was the largest revenue generating type in 2024.
Cervical Cancer Screening is the most lucrative type segment registering the fastest growth during the forecast period.
Country-wise, Germany is expected to register the highest CAGR from 2025 to 2035.
Europe data book summary
Market revenue in 2024
USD 2,370.5 million
Market revenue in 2035
USD 4,252.7 million
Growth rate
5.6% (CAGR from 2025 to 2035)
Largest segment
Cervical cancer screening
Fastest growing segment
Cervical Cancer Screening
Historical data covered
2018 - 2023
Base year for estimation
2024
Forecast period covered
2025 - 2035
Quantitative units
Revenue in USD million
Market segmentation
Cervical Cancer Screening, Cervical Cancer Diagnostics, Pre-cancerous Lesion Treatment
Other key industry trends
In terms of revenue, Europe region accounted for 28.1% of the global cervical cancer screening, diagnostics, and pre-cancerous dysplasia lesion treatment market in 2024.
Globally, North America is projected to lead the regional market in terms of revenue in 2035.
Asia Pacific is the fastest growing regional market and is projected to reach USD 3,288.6 million by 2035.
Europe holds the second-largest share of the cervical cancer screening, diagnostics, and precancerous dysplasia lesion treatment market, propelled by robust government initiatives. According to the WHO, more than 66,000 women in the WHO European Region are diagnosed with cervical cancer annually, with over 30,000 succumbing to the disease.
In August 2020, the World Health Assembly adopted the Global Strategy to eliminate cervical cancer as a public health problem, marking the first global commitment to eradicating a cancer. Building on this momentum, the WHO European Region introduced the Roadmap to Accelerate Elimination of Cervical Cancer (2022–2030), which aims to secure universal access to HPV vaccination, screening, and treatment services.
Europe Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment Market Outlook will help companies and investors design strategic landscapes.
Cervical Cancer Screening was the largest segment with a revenue share of 51.05% in 2024.
Horizon Databook has segmented the Europe cervical cancer screening, diagnostics, and pre-cancerous dysplasia lesion treatment market based on cervical cancer screening, cervical cancer diagnostics, pre-cancerous lesion treatment covering the revenue growth of each sub-segment from 2018 to 2035.
Europe holds the second-largest share of the cervical cancer screening, diagnostics, and precancerous dysplasia lesion treatment market, propelled by robust government initiatives. According to the WHO, more than 66,000 women in the WHO European Region are diagnosed with cervical cancer annually, with over 30,000 succumbing to the disease.
In August 2020, the World Health Assembly adopted the Global Strategy to eliminate cervical cancer as a public health problem, marking the first global commitment to eradicating a cancer. Building on this momentum, the WHO European Region introduced the Roadmap to Accelerate Elimination of Cervical Cancer (2022–2030), which aims to secure universal access to HPV vaccination, screening, and treatment services.
Europe Cervical Cancer Screening, Diagnostics, And Pre-Cancerous Dysplasia Lesion Treatment Market Type Outlook (Revenue, USD Million , 2018-2035)
Cervical Cancer Screening
Cervical Cancer Diagnostics
Pre-cancerous Lesion Treatment
Reasons to subscribe to Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment Market Outlook databook
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment Market Outlook databook
Our clientele includes a mix of Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment Market Outlook companies, investment firms, advisory firms & academic institutions.
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment Market Outlook, including forecasts for subscribers. This continent databook contains high-level insights into Europe Cervical Cancer Screening, Diagnostics, and Pre-cancerous Dysplasia Lesion Treatment Market Outlook from 2018 to 2035, including revenue numbers, major trends, and company profiles.
Europe Cervical Cancer Screening, Diagnostics, And Pre-Cancerous Dysplasia Lesion Treatment Market, 2018-2035 (US$M)